常山药业(300255) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥258,703,492.68, a decrease of 12.10% compared to ¥294,318,791.37 in the same period last year[4] - Net profit attributable to shareholders was ¥3,782,609.17, representing a significant increase of 106.13% from a loss of ¥61,665,097.94 in the previous year[4] - Total operating revenue decreased to ¥258,703,492.68 from ¥294,318,791.37, a decline of approximately 12.1% year-over-year[17] - Net profit for the period was ¥1,627,136.62, recovering from a net loss of ¥62,005,917.65 in the previous period[18] - Operating profit turned positive at ¥2,914,348.74 compared to a loss of ¥59,521,417.38 in the prior year[18] - Total comprehensive income attributable to the parent company was 3,708,458.20, compared to a loss of 61,708,495.97 in the previous period[19] - Basic and diluted earnings per share were both 0.0041, compared to -0.0671 in the previous period, showing a significant improvement[19] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 9.61% to ¥102,992,303.02, primarily due to increased cash payments for goods and services[4] - Net cash flow from operating activities was 102,992,303.02, down from 113,942,876.84 in the previous period, representing a decrease of approximately 16.1%[21] - Cash and cash equivalents increased to ¥280,796,134.44 from ¥236,440,111.55, reflecting a growth of about 18.8%[14] - Cash and cash equivalents at the end of the period totaled 279,163,161.89, compared to 321,940,144.79 at the end of the previous period, indicating a decrease of about 13.3%[22] - Cash inflow from financing activities was 221,606,985.78, down from 507,190,717.70 in the previous period, reflecting a decline of approximately 56.4%[22] - The company reported a net cash flow from financing activities of -31,840,704.28, compared to 25,527,782.28 in the previous period, indicating a significant shift[22] - Cash outflow from investing activities was 29,165,497.16, compared to 48,605,901.53 in the previous period, indicating a decrease of about 40.2%[22] - The company experienced a foreign exchange impact on cash and cash equivalents of 1,176,593.01, compared to -208,032.64 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,548,175,452.32, reflecting a slight increase of 0.56% from ¥4,522,760,540.58 at the end of the previous year[4] - Total liabilities increased to ¥3,007,953,091.53 from ¥2,987,021,269.73, a rise of about 0.7%[15] - The company's total assets reached ¥4,548,175,452.32, up from ¥4,522,760,540.58, indicating a growth of approximately 0.6%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,446[8] - The largest shareholder, Gao Shuhua, holds 30.54% of the shares, amounting to 280,644,728 shares, with 189,189,200 shares pledged[8] - The second-largest shareholder, Yang Minghuan, holds 4.19% of the shares, totaling 38,478,022 shares, with 8,000,000 shares pledged[8] - The total number of shares held by the top 10 shareholders accounts for a significant portion of the company's equity, with the top three shareholders alone holding over 37%[8] - The total number of restricted shares at the end of the period is 2,586,014, with 397,180 shares released from restriction during the period[11] - The company has a total of 2,983,194 restricted shares held by executives, with specific release dates for some shares[11] Expenses and Cost Management - Research and development expenses decreased by 37.95% compared to the previous year, primarily due to reduced direct investment in R&D projects[6] - The company reported a significant reduction in research and development expenses to ¥10,199,286.30 from ¥16,435,989.22, a decrease of approximately 38.0%[18] - The company reported a 70.93% reduction in sales expenses, attributed to changes in marketing strategy following the entry of its main products into national procurement[6] - Total operating costs reduced to ¥262,354,455.18 from ¥355,149,467.25, a decrease of about 26.1% year-over-year[18] Financing Activities - The net cash flow from financing activities decreased by 224.73%, mainly due to a reduction in new borrowings compared to the previous year[7] - Short-term borrowings rose to ¥1,075,228,250.55 from ¥887,546,719.51, an increase of approximately 21.2%[15] Other Information - The company received government subsidies amounting to ¥416,660.72 during the reporting period, which are closely related to its normal business operations[5] - The financial statements for the quarter ending March 31, 2025, are being prepared, indicating ongoing financial reporting activities[12] - The company has not disclosed any significant new strategies or market expansions in the current reporting period[12] - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing activities[10]